European Journal of Cancer
Volume 41, Issue 17 , Pages 2601-2612 , November 2005

Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting

Received 12 April 2005 ,Accepted 18 April 2005.

References 

  1. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888–895
  2. Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol. 2003;21:366–373
  3. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer. A systematic, quantitative review. Cancer. 2001;91:2214–2221
  4. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood. 2002;100:2303–2320
  5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology–cancer and treatment-related anemia, version 2.2004, Jenkintown, PA, USA. <http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf>; [accessed February 16, 2005].
  6. Henry DH. The evolving role of epoetin alfa in cancer therapy. Oncologist. 2004;9:97–107
  7. Cheung WK, Goon BL, Guilfoyle MC, et al. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous dosing to healthy subjects. Clin Pharmacol Ther. 1998;64:412–423
  8. Cheer SM, Wagstaff A. Epoetin beta: a review of its clinical use in the treatment of anaemia in patients with cancer. Drugs. 2004;64:323–346
  9. Glaspy J, Jadeja JS, Justice G, et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer. 2001;84(Suppl. 1):17–23
  10. Egrie JC, Browne JK. Development and characterization of darbepoetin alfa. Oncology. 2002;16(Suppl.):13–22
  11. Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2004;40:2201–2216
  12. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991;50:702–712
  13. Zamboni WC, Stewart CE. An overview of the pharmacokinetic disposition of darbepoetin alfa. Pharmacotherapy. 2002;22:133S–140S
  14. Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31:290–299
  15. Eprex® (epoetin alfa) prescribing information. Janssen-Cilag Ltd., High Wycombe, UK; January 2004.
  16. Eprex® (epoetin alfa) summary of product characteristics. Jansen-Cilag Ltd., High Wycombe, UK; October 2004.
  17. Procrit® (epoetin alfa) prescribing information. Ortho Biotech Products, L.P., Raritan, NJ, USA; June 2004.
  18. Gregory SA, Williams D. Epoetin alfa 60,000 U QW followed by Q2W maintenance dosing corrects anemia and maintains hemoglobin in anemic patients with cancer receiving chemotherapy. Blood. 2003;102:166b;abstract 4373
  19. Langer CJ, Williams D. Anemia correction and hemoglobin maintenance with epoetin alfa 60,000 U QW followed by 80,000 U Q3W in anemic patients with cancer receiving chemotherapy. Blood. 2003;102:166b;abstract 4374
  20. Patton J, Kuzur M, Liggett W, et al. Epoetin alfa 60,000 U once weekly followed by 120,000 U every three weeks maintains hemoglobin levels in anemic cancer patients receiving chemotherapy: final report. Oncologist. 2004;9:90–96
  21. NeoRecormon® (epoetin beta) prescribing information. Roche Pharmaceuticals, Basel, Switzerland; March 2003.
  22. European approval launches more convenient and cost-effective delivery of once weekly NeoRecormon for patients with lymphoid cancers. <http://www.roche.com/inv-update-2004-03-02>; [accessed September 8, 2004].
  23. Aranesp® (darbepoetin alfa) prescribing information. Amgen, Thousand Oaks, CA, USA; December 12, 2003.
  24. Amgen Inc. Aranesp approved for extended dosing by European Commission. <http://www.amgen.com/news/viewPR.jsp?id=616912>; [accessed September 27, 2004].
  25. Hesketh PJ, Arena F, Patel D, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer. 2004;100:859–868
  26. Thames W, Yao B, Scheifele A, et al. Drug use evaluation (DUE) of darbepoetin alfa in anemic patients undergoing chemotherapy supports a fixed dose of 200 mcg Q2W given every 2 weeks (Q2W). Proc Am Soc Clin Oncol. 2003;22:546;abstract 2196
  27. Schwartzberg L, Shiffman R, Tomita D, et al. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther. 2003;25:2781–2796
  28. Dammacco F, Castoldi G, Rödjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001;113:172–179
  29. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001;19:2865–2874
  30. Quirt I, Robeson C, Lau Y, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol. 2001;19:4126–4134
  31. Crawford J, Demetri GD, Gabrilove JL, et al. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer. 2002;3:180–190
  32. Demetri GD, Gabrilove JL, Blasi MV, et al. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer. 2002;3:45–51
  33. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875–2882
  34. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer. 2003;98:1072–1079
  35. Shasha D, George M. Rapid hemoglobin response in anemic cancer patients undergoing chemotherapy or chemoradiation therapy receiving once-weekly epoetin alfa treatment. Blood. 2002;100:17b;abstract 3517
  36. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005;23(12):2606–2617
  37. Littlewood TJ, Nortier J, Rapoport B, et al. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. Hematol Oncol. 2003;21:169–180
  38. Österborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol. 2002;20:2486–2494
  39. Cazzola M, Beguin Y, Kloczko J, et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol. 2003;122:386–393
  40. Boogaerts M, Coiffier B, Kainz C, for the Epoetin Beta QOL Working Group. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 2003, 88, 988–995.
  41. Glossmann JP, Engert A, Wassmer G, et al. Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy – results of a randomized trial. Ann Hematol. 2003;82:469–475
  42. Johansson JE, Wersall P, Brandberg Y, Andersson SO, Norstrom L, for the EPO-Study Group. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer – a randomized study. Scand J Urol Nephrol 2001, 35, 288–294.
  43. Kunikane H, Watanabe K, Fukuoka M, et al. Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol. 2001;6:296–301
  44. Olsson AM, Svensson JH, Sundstrom J, et al. Erythropoietin treatment in metastatic breast cancer – effects on Hb, quality of life and need for transfusion. Acta Oncol. 2002;41:517–524
  45. Coiffer B. Rapid response with epoetin beta (NeoRecormon) once weekly or three times weekly in anemic patients with lymphoid malignancies. Blood. 2003;102:18b–19babstract 3775
  46. Bokemeyer C, Littlewood T, Aapro M. Is once-weekly epoetin beta “highly effective” in treating anaemia in patients with lymphoproliferative malignancy? (letter). Br J Haematol. 2004;125:98–99
  47. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer. 2002;87:268–276
  48. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer. 2003;39:2026–2034
  49. Smith RE, Tchekmedyian NS, Chan D, et al. A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer. 2003;88:1851–1858
  50. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211–1220
  51. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol. 2003;122:394–403
  52. Glaspy JA, Jadeja JS, Justice G, et al. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer. 2003;97:1312–1320
  53. Chang J, Couture F, Young S, et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol. 2005;23(12):2597–2605
  54. Hudis CA, Williams D. Early treatment of mild anemia with once-weekly epoetin alfa significantly improves hemoglobin and quality of life in early-stage breast cancer patients during conventional adjuvant chemotherapy. Breast Cancer Res Treat. 2003;82(Suppl. 1):S154;abstract 639
  55. Littlewood TJ, Bajetta E, Rapoport B, et al. Early administration of epoetin alfa optimizes anemia management with respect to hematologic and quality of life (QOL) outcomes in anemic cancer patients (pts) undergoing chemotherapy. Blood. 2002;100(11 Pt 2):18b–19babstract 3524
  56. Crawford J, Robert F, Perry M, et al. Epoetin alfa 40,000 U once weekly maintains hemoglobin in advanced non-small-cell lung cancer patients receiving first-line chemotherapy. Proc Am Soc Clin Oncol. 2003;22:628;abstract 2527
  57. Straus DJ, Testa M, Riggs SA, et al. Early treatment with epoetin alfa improves anemia, quality of life (QOL), and productivity in patients (pts) with hematologic malignancies and mild anemia during chemotherapy (CT). Blood. 2003;102:497a;abstract 1811
  58. Richart JM, Petruska PJ, Klebert KS, et al. A phase III trial of epoetin-alfa: early vs late administration in patients treated with chemotherapy. Blood. 2002;100:175b;abstract 4199
  59. Bohlius JF, Langensiepen S, Schwarzer G, et al. Does erythropoietin improve overall survival in the treatment of patients with malignant diseases? Results of a comprehensive meta-analysis. Blood. 2003;102:203a;abstract 709
  60. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255–1260
  61. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459–460
  62. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005;23(25):5960–5972
  63. Boccia R, Davidson S, Tomita D, et al. Usage and clinical outcomes of erythropoietic proteins for the treatment of chemotherapy-induced anemia (CIA): clinical evaluation of anemia response (CLEAR), a multicenter, retrospective cohort study. Blood. 2003;102:748a–749aabstract 2761
  64. Fahrbach KR, Frame D, Scheye R, et al. Comparison of anemia treatment outcomes in patients with cancer receiving epoetin alfa and darbepoetin alfa. Blood. 2003;102:510b–511babstract 5774
  65. Mirtsching B, Charu V, Vadhan-Raj S, et al. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis. Oncology (Huntingt). 2002;16(10 Suppl. 11):31–36
  66. Waltzman R, Fesen M, Justice GR, et al. Epoetin alfa 40,000 U QW vs darbepoetin alfa 200 mcg Q2W in anemic cancer patients receiving chemotherapy: Preliminary results of a phase 3 randomized trial (poster). Presented at the American Society of Clinical Oncology 40th Annual Meeting, June 5–8, 2004, New Orleans, LA, USA. Also, Proc Am Soc Clin Oncol 2004, 23, 763, [abstract 8153].
  67. Schwartzberg LS, Yee LK, Senecal FM, et al. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist. 2004;9:696–707
  68. Rosberg J, Lefebvre P, Fastenau J, et al. Clinical significance of a ⩾1 g/dL rise in hemoglobin at week 4 (early response) or at week 8 during epoetin alfa treatment. Blood. 2003;102:753a;abstract 2777

PII: S0959-8049(05)00728-8

doi: 10.1016/j.ejca.2005.04.046

European Journal of Cancer
Volume 41, Issue 17 , Pages 2601-2612 , November 2005

Article Tools